<DOC>
	<DOCNO>NCT00570661</DOCNO>
	<brief_summary>The present study design order evaluate safety tolerability ITF2357 patient active SOJIA inadequate response intolerance standard therapy oral steroid methotrexate , without previously use biologic agent , preliminary evaluation efficacy ITF2357 treatment SOJIA . ITF2357 administer orally daily cumulative dose 1.5 mg/kg : dose children/young adult consider roughly equivalent dose 1 mg/kg/day adult , far proven free relevant safety concern healthy volunteer patient .</brief_summary>
	<brief_title>Phase II , Open Label , International , Multicentre Clinical Trial Investigate Safety Efficacy Oral ITF2357 Patients With Active Systemic Onset Juvenile Idiopathic Arthritis ( SOJIA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Givinostat hydrochloride</mesh_term>
	<criteria>1 . Established diagnosis Systemic SOJIA accord ILAR criterion least six month study entry , inadequate response intolerance standard therapy oral steroid and/or methotrexate , without previously use biologic agent . 2 . Active disease least one month prior enrolment define follow criterion : Presence arthritis plus least one following : Fever , define body temperature &gt; = 37,5 C degree least day least five consecutive day presence typical SOJIA intermittent temperature chart Rash , define presence typical SOJIA salmon pink rash trunk elsewhere febrile episode Serositis ( pericarditis , pleuritis , peritonitis ) confirm ultrasound and/or Xray exploration presence typical ECG finding case pericarditis Lymphadenopathy , define lymph node enlargement 1,5 cm localize anywhere within body , and/or hepatomegaly and/or splenomegaly , confirm ultrasound evaluation establish comparison age standard organ size ESR &gt; = 20 mm/h ( first hour ) and/or CRP &gt; = 10 mg/L . absence arthritis , two definite one definite one probable diagnostic criterion plus ESR &gt; =20 mm/h ( first hour ) and/or CRP &gt; =10 mg/L 3 . Age enrolment 2 25 year 4 . Age first SOJIA diagnosis &lt; 16 year 5 . Previously introduced standard treatment disease steroid without satisfactory effect concomitant treatment oral steroid dose equivalent &gt; = 0,2 mg/kg/day prednisolone , unmodified least four week patient 's enrolment 6 . In case concomitant methotrexate treatment , stable dose &gt; = 10mg/m2 weekly al least 4 week pt enrollment 7 . Previous treatment biologics , , least three month without satisfactory effect drug intolerability , discontinue least period specify patient 's enrolment : Two month etanercept Six month infliximab 8 . Other diseasemodifying antirheumatic drug possibly previously introduce discontinued period least five half live 9 . Concomitant nonsteroidal antiinflammatory drug , , stable dose least four week patient 's enrolment 10 . Female childbearing potential , use safe contraceptive measure 11 . Signed write informed consent start study procedure 1 . Ongoing clinical relevant viral infection ( eg . : Herpes Zoster , Ebstein barr , CMV , Systemic fungal infection history recurrent serious bacterial infection ) 2 . History macrophage activation syndrome 3 . Clinically significant illness i.e . condition ( include laboratory abnormality ) opinion Investigator place patient unacceptable risk adverse outcome he/she participate study 4 . Psychiatric illness/social situation would limit compliance study medication protocol requirement 5 . Congenital heart and/or central nervous system disorder 6 . Inherited metabolic disease 7 . Positive serological test anti HCV , anti HIV HBsAg ( perform screen ) 8 . Pregnant lactate woman 9 . Presence malignancy 10 . Any previous evidence , irrespective severity , coronary disease , cardiac rhythm abnormality congestive heart failure 11 . QTc interval &gt; 450 msec screen evaluation 12 . Serum magnesium potassium LLN screen 13 . Unavoidable concomitant treatment drug know potential risk cause Torsades de Pointes</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>